Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis

Bosn J Basic Med Sci. 2007 May;7(2):103-6. doi: 10.17305/bjbms.2007.3061.

Abstract

Tissue angiotensin-converting enzyme (ACE) was measured in 60 patients with psoriasis and in 20 healthy individuals. According to clinical forms of psoriasis, patients were further divided into three groups: psoriasis with solitary lesions (n=20), psoriasis with multiple disseminated lesions (n=20) and erythrodermic psoriasis (n=20). The tissue ACE activity was determined before and after therapy, by the spectrophotometric method using hippuryl-l-histidyl-l-leucine as a substrate. The enzyme activity is expressed in units: 1 U corresponds to 1 nmol of hippuric acid released by hydrolysis of hippuryl-l-histidyl-l-leucine per minute and 50 mg of the tissue. Before therapy, tissue ACE activity was significantly increased in patients with psoriasis (4,14+/-0,34; X+/-SEM) in comparison to healthy individuals (1,86+/-0,16). The greatest increase in tissue ACE activity was observed in patients with erythrodermic psoriasis (4,72+/-0,65), followed by those with multiple disseminated lesions (4,24+/-0,63) and solitary psoriatic lesions (3,47+/-0,48). After therapy, serum ACE activity was significantly decreased in all clinical forms of the disease. Determination of tissue ACE activity might be a good non-specific parameter for assessment therapeutic effects.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • Biopsy
  • Case-Control Studies
  • Dermatologic Agents / therapeutic use
  • Diagnosis, Differential
  • Female
  • Gene Expression Regulation, Enzymologic
  • Humans
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Peptidyl-Dipeptidase A / genetics
  • Peptidyl-Dipeptidase A / metabolism*
  • Photochemotherapy / methods
  • Psoriasis / drug therapy
  • Psoriasis / enzymology*
  • Psoriasis / pathology
  • Skin / enzymology*
  • Skin / pathology

Substances

  • Biomarkers
  • Dermatologic Agents
  • Peptidyl-Dipeptidase A
  • Methotrexate